Hanzhang Xie - Publications

Vitiligo secondary to immunosuppressants: a pharmacovigilance study of the FDA Adverse Event Reporting System.

Journal: Frontiers in immunology

Published: September 17, 2025

Melanosis Secondary to Drugs: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS).

Journal: Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)

Published: March 07, 2025

Mining and analysis of adverse event signals of isotretinoin based on the real-world data of FAERS database.

Journal: Frontiers in medicine

Published: January 13, 2025

Melasma secondary to drugs: a real-world pharmacovigilance study of the FDA adverse event reporting system (FAERS).

Journal: BMC pharmacology & toxicology

Published: December 03, 2024

Real world pharmacovigilance study of antineoplastic drug related vitiligo risks.

Journal: Scientific reports

Published: November 23, 2024

Drug-induced dermatomyositis: a pharmacovigilance study of the FDA adverse event reporting system.

Journal: Frontiers in pharmacology

Published: November 12, 2024

Linear IgA bullous dermatosis secondary to drugs: a real-world pharmacovigilance study of the FDA adverse event reporting system.

Journal: Frontiers in medicine

Published: November 02, 2024

Association between sugar-sweetened beverages and pure fruit juice with risk of six cardiovascular diseases: a Mendelian randomization study.

Journal: European journal of clinical nutrition

Published: November 12, 2023